BRAF V600E突变转移性结直肠癌治疗进展
Treatment progress of BRAF V600E-mutated metastatic colorectal cancer
彭炜惟 1沙欢欢 1方瑛 1邬芝雅 1周国仁1
作者信息
- 1. 江苏省肿瘤医院肿瘤内科 江苏省肿瘤防治研究所 南京医科大学附属肿瘤医院,南京 210009
- 折叠
摘要
结直肠癌是最常见的消化道恶性肿瘤,约10％的转移性结直肠癌(mCRC)患者携带BRAF V600E突变,携带这种突变的患者具有独特的分子特征和临床表型.其全身化疗的效果较差,对BRAF抑制剂单药不敏感,且生存率较低,因此开发新的治疗药物及临床策略以改善这些患者预后意义重大.文章阐述BRAF V600E突变mCRC的治疗方案以及合理衍生的靶向药物和免疫疗法的组合.
Abstract
Colorectal cancer is the most common malignant tumor of digestive tract,and BRAF V600E mutations occur in approximately 10％of patients with metastatic colorectal cancer(mCRC).Cancer patients harboring this mutation have a unique molecular profile and clinical phenotype;they show poor response to systemic chemotherapy,insensitivity to single BRAF inhibitor,and short survival rate.It is important to develop new therapeutic agents and clinical strategies to improve the prognosis of these patients.This review mainly introduces treatment methods for BRAF V600E-mutated mCRC and rationally derived combinations of targeted agents and immunotherapy.
关键词
结直肠肿瘤/BRAF/V600E突变/免疫疗法/分子靶向治疗Key words
Colorectal neoplasms/BRAF V600E mutation/Immunotherapy/Molecular targeted therapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据